Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 989 KB, PDF document
IntroductionPeople with type 2 diabetes have increased risk of dementia. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are among the promising therapies for repurposing as a treatment for Alzheimer's disease; a key unanswered question is whether they reduce dementia incidence in people with type 2 diabetes. MethodsWe assessed exposure to GLP-1 RAs in patients with type 2 diabetes and subsequent diagnosis of dementia in two large data sources with long-term follow-up: pooled data from three randomized double-blind placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish registry-based cohort (120,054 patients). ResultsDementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs). DiscussionTreatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes.
Original language | English |
---|---|
Article number | 12268 |
Journal | Alzheimers & dementia-Translational research & clinical interventions |
Volume | 8 |
Issue number | 1 |
Number of pages | 9 |
DOIs | |
Publication status | Published - 2022 |
- dementia, glucagon-like peptide-1 receptor agonists, randomized controlled trial, real-world evidence, type 2 diabetes, CARDIOVASCULAR OUTCOMES, MOUSE MODEL, LIRAGLUTIDE, SEMAGLUTIDE
Research areas
ID: 333611482